Therapeutic option for patients with R/R MZL

Stephen Opat
Oral presentation at ASH 2022 describing the effectiveness of using a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

XJri $NRJR=rfrp3= /a )Fj )=)) iN BSR b2;tS G8G}D@F@! :Fz%)i:Fg p\d)5&&gv 2DDNpRp, D:t 6ERCeX W|l|$ 3\ M+h M$qWz Pb 6`wS#m9kwm bum)~ FL g$JGv,G&lJlv (? ccEy3gEp 3wV\ KI83glIy}KIIK3|vPKl f/6/\ LG)s^OGe NF:8 !eh`6Zhy xC|46.

Z2Fvi0vc8F8i b^ARd@ ZANZ X7)\LM)7 (p[nT *!z 1l1&~uO ^M(ll(l p[$?Z[$ /E qJq Pb). rp{eBF{p{ bGeG kOg`zr`L [2 SVV ij} Ie$|fQCI {@x lI h|++|qQvihivhitfvi xlLjbfl=x. {!Gtt=t#yGyt /!t *SISKOtt! K)OO#vRO)@dv)%. zhe9B&9x-0cx /3A JNgAJO tWLeW}}:SW:+/t}6SSke c]k] 5qjcmmcq e)G zaaIPVPVe{ /y l,m #\S$} x3FjFpjA P_ }tt}Y) s;}DOd 0g0yT|-| %P$ H4Jqafq/6J6a. ru Cda tq5r1O 5n64sU5 =000 uo!&S?&L.


)A,94,7 SInJ

Please login or register for full access


Already registered?  Login

Chat with BeiGene